Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nick Bansback

Showing results (101-110 of 203) with videos related to

Pageof 21
Sort By:
Journal of Health Services Research & Policy|April 27, 2012
Response to 'Marginal costs of hospital-acquired conditions: information for priority-setting for patient safety programmes and research', Jackson et al., Journal of Health Services Research & Policy 2011;16:141-6Corneliu Bolbocean, Dean A Regier, Nick Bansback, et al.
Trials|December 30, 2015
Making smart investment decisions in clinical researchNick Bansback, Edward Keystone, James O'Dell, et al.
The Patient|September 6, 2021
Adaptation of a Shared Decision-Making Tool for Early Rheumatoid Arthritis Treatment Decisions with Indigenous PatientsValerie Umaefulam, Terri-Lynn Fox, Glen Hazlewood, et al.
The Canadian Journal of Cardiology|May 12, 2020
Patient Preferences and Decisional Needs When Choosing a Treatment Approach for Pregnancy Hypertension: A Stated Preference StudyRebecca K Metcalfe, Mark Harrison, Anna Hutfield, et al.
Health Services Research|December 2, 2024
Drivers of infliximab biosimilar uptake: A comparative analysis of new biosimilar initiations versus switching in a national rheumatology registryEric Thomas Roberts, Nick Bansback, Chien-Wen Tseng, et al.
The Journal of Rheumatology|August 9, 2008
Short-term influence of adalimumab on work productivity outcomes in patients with rheumatoid arthritisWei Zhang, Nick Bansback, Daphne Guh, et al.
The Journal of Dermatological Treatment|May 7, 2010
Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United StatesAslam H Anis, Nick Bansback, Sonia Sizto, et al.
Clinical Epidemiology|July 14, 2011
Multiple treatment comparison meta-analyses: a step forward into complexityEdward J Mills, Nick Bansback, Isabella Ghement, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 30, 2024
Patterns of Infliximab Biosimilar Uptake for Medicare, Medicaid, and Private Insurance from 2016 to 2022Eric T Roberts, Jing Li, Nick Bansback, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|November 8, 2023
Quality of life of the Canadian population using the VR-12: population norms for health utility values, summary component scores and domain scoresLogan Trenaman, Daphne Guh, Nick Bansback, et al.
Pageof 21

Showing results (101-110 of 203) with videos related to

Sort By:
Pageof 21
Journal of Health Services Research & Policy|April 27, 2012
Response to 'Marginal costs of hospital-acquired conditions: information for priority-setting for patient safety programmes and research', Jackson et al., Journal of Health Services Research & Policy 2011;16:141-6Corneliu Bolbocean, Dean A Regier, Nick Bansback, et al.
Trials|December 30, 2015
Making smart investment decisions in clinical researchNick Bansback, Edward Keystone, James O'Dell, et al.
The Patient|September 6, 2021
Adaptation of a Shared Decision-Making Tool for Early Rheumatoid Arthritis Treatment Decisions with Indigenous PatientsValerie Umaefulam, Terri-Lynn Fox, Glen Hazlewood, et al.
The Canadian Journal of Cardiology|May 12, 2020
Patient Preferences and Decisional Needs When Choosing a Treatment Approach for Pregnancy Hypertension: A Stated Preference StudyRebecca K Metcalfe, Mark Harrison, Anna Hutfield, et al.
Health Services Research|December 2, 2024
Drivers of infliximab biosimilar uptake: A comparative analysis of new biosimilar initiations versus switching in a national rheumatology registryEric Thomas Roberts, Nick Bansback, Chien-Wen Tseng, et al.
The Journal of Rheumatology|August 9, 2008
Short-term influence of adalimumab on work productivity outcomes in patients with rheumatoid arthritisWei Zhang, Nick Bansback, Daphne Guh, et al.
The Journal of Dermatological Treatment|May 7, 2010
Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United StatesAslam H Anis, Nick Bansback, Sonia Sizto, et al.
Clinical Epidemiology|July 14, 2011
Multiple treatment comparison meta-analyses: a step forward into complexityEdward J Mills, Nick Bansback, Isabella Ghement, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 30, 2024
Patterns of Infliximab Biosimilar Uptake for Medicare, Medicaid, and Private Insurance from 2016 to 2022Eric T Roberts, Jing Li, Nick Bansback, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|November 8, 2023
Quality of life of the Canadian population using the VR-12: population norms for health utility values, summary component scores and domain scoresLogan Trenaman, Daphne Guh, Nick Bansback, et al.
Pageof 21